GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » ROC (Joel Greenblatt) %

Myos Rens Technology (Myos Rens Technology) ROC (Joel Greenblatt) % : -187.04% (As of Sep. 2020)


View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Myos Rens Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -187.04%.

The historical rank and industry rank for Myos Rens Technology's ROC (Joel Greenblatt) % or its related term are showing as below:

MYOS's ROC (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.85
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Myos Rens Technology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Myos Rens Technology ROC (Joel Greenblatt) % Historical Data

The historical data trend for Myos Rens Technology's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myos Rens Technology ROC (Joel Greenblatt) % Chart

Myos Rens Technology Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -205.82 -270.56 -253.98 -212.98 -216.64

Myos Rens Technology Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -190.89 -279.89 -205.67 -166.18 -187.04

Competitive Comparison of Myos Rens Technology's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myos Rens Technology's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's ROC (Joel Greenblatt) % falls into.



Myos Rens Technology ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.033 + 1.474 + 0.187) - (0.108 + 0 + 0.0030000000000001)
=1.583

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.06 + 1.368 + 0.094) - (0.127 + 0 + 0.004)
=1.391

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Myos Rens Technology for the quarter that ended in Sep. 2020 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2020  Q: Sep. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.232/( ( (0.253 + max(1.583, 0)) + (0.229 + max(1.391, 0)) )/ 2 )
=-3.232/( ( 1.836 + 1.62 )/ 2 )
=-3.232/1.728
=-187.04 %

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myos Rens Technology  (NAS:MYOS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Myos Rens Technology ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myos Rens Technology (Myos Rens Technology) Business Description

Traded in Other Exchanges
N/A
Address
45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927
Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.
Executives
Joseph Mannello director, officer: Chief Executive Officer C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel director PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock director C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey director 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne director 4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas director 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin 10 percent owner
John Nosta director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren director, 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc 10 percent owner 150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019

Myos Rens Technology (Myos Rens Technology) Headlines

From GuruFocus